Christopher J. Hindley

Insmed (United Kingdom) — United Kingdom

Biochemistry, Genetics and Molecular Biology · Life Sciences

21h-index2.8kcitations56works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(16), Pancreatic function and diabetes(13), Synthesis and biological activity(12), Pluripotent Stem Cells Research(5), Bone fractures and treatments(5)

Publications56 total

The identification of functional regions of MEK1 using CRISPR tiling screens
Communications Biology·2025Open Access
Abstract B164: ASTX029 is a dual mechanism ERK1/2 inhibitor with activity in models of MAPK-inhibitor resistance
Molecular Cancer Therapeutics·2023
Abstract A110: Identifying sensitive patient populations for CDK7 inhibitors using cell panel screens and bioinformatic approaches
Molecular Cancer Therapeutics·2023
Abstract A43: Targeting ERK1/2 overcomes resistance to venetoclax by altering Drp1-dependent mitochondrial fission and metabolism in AML
Blood Cancer Discovery·2023
Abstract 3860: ERK1/2 inhibition overcomes resistance to venetoclax in AML by altering mitochondrial metabolism
Cancer Research·2023· 1 cited
Data from ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK
2023Open Access
Supplementary Methods from ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK
2023Open Access
Supplementary Tables 1-6 from ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK
2023Open Access
Supplementary Figures 1-7 from ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK
2023Open Access
Supplementary Tables 1-6 from ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK
2023Open Access
Data from ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK
2023Open Access
Supplementary Methods from ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK
2023Open Access
Supplementary Figures 1-7 from ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK
2023Open Access
Inhibition of ERK1/2 Reverses Venetoclax-Induced Autophagy to Overcome Resistance in Acute Myeloid Leukemia
Blood·2022· 2 cited
ERK1/2 Inhibition Overcomes Resistance to Venetoclax in AML By Altering Drp1-Dependent Mitochondrial Fission and Metabolism
Blood·2022· 1 cited
Abstract P112: Treatment with the dual-mechanism ERK inhibitor, ASTX029, alters myeloid cell differentiation
Molecular Cancer Therapeutics·2021
ERK1/2 Inhibition Overcomes Resistance in Acute Myeloid Leukemia (AML) and Alters Mitochondrial Dynamics
Blood·2021· 4 cited
ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK
Molecular Cancer Therapeutics·2021· 32 citedOpen Access
Anti-Tumor Activity of ASTX029, a Dual Mechanism Inhibitor of ERK1/2, in Preclinical AML Models
Blood·2020· 1 cited
The clinical candidate, ASTX029, is a novel, dual mechanism ERK1/2 inhibitor and has potent activity in MAPK-activated cancer cell lines and in vivo tumor models
European Journal of Cancer·2020
page 1 of 3Next →

Frequent Co-authors

Meritxell Huch(14), Anna Philpott(11), Joanne M. Munck(11), Benjamin D. Simons(10), John F. Lyons(10), Nicola G. Wallis(10), Nicola E. Wilsher(9), Nicole Prior(8), Luke Bevan(7), Jessica L. Brothwood(7), Aurélie Courtin(7), Charlotte East(7), Justyna Kucia-Tran(7), Sandra Muench(7), Alpesh Shah(7), Martin Sims(7), Gianmarco Mastrogiovanni(6), Valério Berdini(6), Roberta Ferraldeschi(6), Tom D. Heightman(6)